A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated "brain fog".BOSTON, ...
AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a ...
SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...
A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how ...
Professor Jan Terje Andersen, Oslo University Hospital, will give a lecture on Antibody designs on 8 April from 16.00-17.00 in DDW-M2.01.
What the research is about When you catch a cold, an invisible battle takes place inside your body. In this battle ...
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Scientists at Nuremberg Hospital and Paracelsus Medical University have succeeded in developing the world’s first monoclonal antibody that specifically and sensitively detects vasoinhibin — also known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results